Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a...

Area of Science:

• Dermatology
• Immunology
• Clinical Trials

Background:

• Moderate-to-severe atopic dermatitis (AD) significantly impacts patients' quality of life.
• Previous studies showed rocatinlimab improved clinical measures of AD severity.
• A post hoc analysis assessed rocatinlimab's impact on patient-reported outcomes (PROs).

Purpose of the Study:

• To analyze the disease burden in adults with moderate-to-severe AD.
• To evaluate the effect of rocatinlimab on patient-reported outcomes (PROs).
• To assess the correlation between PROs and clinical disease severity scores.

Main Methods:

• Analysis of baseline data from a phase 2b, randomized, double-blind study.
• Inclusion of 267 adult subjects with moderate-to-severe AD.
• Assessment of Worst Pruritus NRS, Sleep Disturbance NRS, and Dermatology Life Quality Index (DLQI).
• Statistical analysis using mixed models for repeated measures.

Main Results:

• Rocatinlimab demonstrated significant improvements in Worst Pruritus, Sleep Disturbance, and DLQI scores.
• PRO improvements were evident by week 18 and maintained through week 36.
• Benefits on PROs persisted for at least 20 weeks after treatment cessation.
• PRO scores showed varied correlations with clinical severity scores (SCORAD, EASI).

Conclusions:

• Patient-reported outcomes are essential for a comprehensive understanding of AD treatment benefits.
• Rocatinlimab effectively alleviates symptoms and improves quality of life in AD patients.
• The positive impact of rocatinlimab on PROs is rapid and sustained.